Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 27,200 KRW
Change Today -150.00 / -0.55%
Volume 406.0K
054670 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 2:28 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for daehan new pharm co ltd (054670)

Year over year, Daehan New Pharm Co., Ltd. has been able to grow revenues from 56.7B KRW to 71.9B KRW. Most impressively, the company has been able to reduce the percentage of sales devoted to income tax expense from 6.59% to 1.33%. This was a driver that led to a bottom line growth from a loss of 2.0B KRW to a gain of 2.7B KRW.
View Income Statement In U.S. Dollar
Currency in
Millions of South Korean Wons
As of:Dec 31
2011
KRW
Dec 31
2012
KRW
Dec 31
2013
KRW
Dec 31
2014
KRW
4 Year
Trend
Revenues44,522.748,010.256,702.471,940.4
Other Revenues0.0------
TOTAL REVENUES44,522.748,010.256,702.471,940.4
Cost of Goods Sold21,990.224,150.925,808.732,967.5
GROSS PROFIT22,532.523,859.430,893.738,972.9
Selling General & Admin Expenses, Total16,609.225,012.923,803.930,642.5
R&D Expenses37.97.318.391.2
Depreciation & Amortization, Total305.6898.9965.11,015.0
Other Operating Expenses222.1225.6270.1290.8
OTHER OPERATING EXPENSES, TOTAL17,174.826,144.625,057.332,039.4
OPERATING INCOME5,357.7-2,285.35,836.46,933.5
Interest Expense-3,074.4-3,388.9-3,779.9-2,740.0
Interest and Investment Income173.2214.5306.7200.6
NET INTEREST EXPENSE-2,901.2-3,174.4-3,473.2-2,539.4
Currency Exchange Gains (Loss)119.1-433.0-205.2278.8
Other Non-Operating Income (Expenses)-1,641.9425.3-375.0-1,056.7
EBT, EXCLUDING UNUSUAL ITEMS933.7-5,467.51,782.93,616.2
Gain (Loss) on Sale of Assets-0.74.5----
EBT, INCLUDING UNUSUAL ITEMS932.9-5,463.01,782.93,616.2
Income Tax Expense289.465.93,737.9954.7
Earnings from Continuing Operations643.6-5,528.9-1,955.02,661.4
NET INCOME643.6-5,528.9-1,955.02,661.4
NET INCOME TO COMMON INCLUDING EXTRA ITEMS643.6-5,528.9-1,955.02,661.4
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS643.6-5,528.9-1,955.02,661.4
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
054670:KS 27,200.00 KRW -150.00

054670 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 054670.
View Industry Companies
 

Industry Analysis

054670

Industry Average

Valuation 054670 Industry Range
Price/Earnings 100.0x
Price/Sales 5.4x
Price/Book 5.3x
Price/Cash Flow 107.4x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEHAN NEW PHARM CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.